EP Patent

EP3102564A1 — Tablet formulation for cgrp-active compounds

Assigned to Merck Sharp and Dohme LLC · Expires 2016-12-14 · 9y expired

What this patent protects

The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein "R a " is independently H or -F, in a water-soluble polymer matrix which further comprises a disintegration…

USPTO Abstract

The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein "R a " is independently H or -F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.

Drugs covered by this patent

Patent Metadata

Patent number
EP3102564A1
Jurisdiction
EP
Classification
—
Expires
2016-12-14
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.